title: Associations between joint space narrowing and molecular markers of collagen and proteoglycan turnover in patients with knee osteoarthritis.
abstract: OBJECTIVE
  We examined whether plasma concentrations of biomarkers of the collagenase cleavage of type II collagen (C2C), types I and II collagens (C1,2C), type II collagen synthesis (CPII), proteoglycan aggrecan turnover (CS846), and the ratio C2C:CPII would distinguish subjects with progressive radiographic osteoarthritis (OA) from those with stable disease.
  
  
  METHODS
  Subjects were 120 obese middle-aged women with unilateral knee OA who participated in a 30-month clinical trial of structure modification with doxycycline, in which a standardized semiflexed anteroposterior view of the knee was obtained at baseline, 16 months, and 30 months. Subjects were selected from a larger sample to permit a priori comparisons between 60 OA progressors and 60 nonprogressors, as defined by joint space narrowing (JSN) in the medial tibiofemoral compartment. Each group contained 30 subjects who exhibited clinically significant increases in knee pain over 30 months and 30 who did not. Plasma samples were obtained every 6 months for determination of C2C, CPII, CS846, and C1,2C.
  
  
  RESULTS
  None of the biomarkers was a significant predictor of progression of JSN. Over the interval from baseline to 16 months, the mean and the maximum of the intercurrent CS846 values were significantly associated with JSN (i.e., 0.12-0.14 mm of JSN per SD decrease in mean or maximum CS846; p < 0.01). The mean of serial CS846 levels was related to JSN also during the interval between months 16 and 30.
  
  
  CONCLUSIONS
  Markers of type II collagen synthesis/degradation and of proteoglycan aggrecan turnover were not predictive of JSN in knee OA in this pilot study. However, serial concentrations of proteoglycan aggrecan epitope CS846 were associated with JSN during both the intervals studied.
authors.affiliation: Department of Medicine, Indiana University School of Medicine, Indianapolis, USA. smazzuca@iupui.edu
authors.forename: Steven A
authors.initials: SA
authors.lastname: Mazzuca
authors.forename: A Robin
authors.initials: AR
authors.lastname: Poole
authors.forename: Kenneth D
authors.initials: KD
authors.lastname: Brandt
authors.forename: Barry P
authors.initials: BP
authors.lastname: Katz
authors.forename: Kathleen A
authors.initials: KA
authors.lastname: Lane
authors.forename: Tatiana
authors.initials: T
authors.lastname: Lobanok
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D003094:Collagen / Q000097:blood*; D018450:Disease Progression; D004318:Doxycycline / Q000627:therapeutic use; D005260:Female; D006801:Humans; D031221:Knee Dislocation / Q000000981:diagnostic imaging / Q000378:metabolism / Q000473:pathology*; D007719:Knee Joint / Q000473:pathology*; D008875:Middle Aged; D009765:Obesity; D020370:Osteoarthritis, Knee / Q000097:blood / Q000188:drug therapy / Q000473:pathology*; D011509:Proteoglycans / Q000097:blood*; D011859:Radiography; D016474:Weight-Bearing
chemical_list: D000900:Anti-Bacterial Agents; D015415:Biomarkers; D011509:Proteoglycans; D003094:Collagen; D004318:Doxycycline